NWBO News and Press, Northwest Biotherapeutics Inc. From 08/11/20

Northwest Biotherapeutics ( OTCQB:NWBO ) : Q2 GAAP EPS of -$0.08. More news on: Northwest Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BETHESDA, Md. , Aug. 11, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for a...

BETHESDA, Md. , July 24, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Com...

The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...

Northwest Biotherapeutics ( OTCQB:NWBO ): Q1 GAAP EPS of $0.00. Revenue of $0.57M (+67.6% Y/Y) Press Release More news on: Northwest Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

BETHESDA, Md. , June 2, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Gl...

In April, Northwest Biotherapeutics   (OTC: NWBO) disclosed that its phase 3 clinical trial to evaluate its cancer immunotherapy vaccine DCVax-L in treating glioblastoma, the most invasive form of brain cancer, may finally be coming to an end. The company believes it will reach the r...

BETHESDA, Md. , April 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers , will discuss the projected schedule f...

BETHESDA, Md. , Feb. 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder's Meeting will be held on April 18, 2020 ...

Company Thesis Northwest Biotherapeutics' ( NWBO ) flagship product, DCVax (Dendritic cell vaccine for the treatment of glioblastoma) has seen its clinical investigation running well beyond schedule. While preliminary results on the entire study population are out, they raise more questions ...